Nasdaq:AGIO
AGIOS PHARMACEUTICALS, INC.
A precision medicine innovator leveraging proprietary small molecule technologies to develop targeted therapies for oncology and rare diseases.
Key Metrics
Investment Thesis
Bull Case
Agios offers compelling value for investors seeking exposure to high-growth oncology and rare disease sectors with a differentiated pipeline of precision medicines. The company's substantial cash reserves relative to current liabilities provide a runway to advance clinical programs without immediate equity dilution, while recent revenue acceleration suggests commercial validation of their core assets.
Bear Case
The persistent negative net income and high operating expenses pose significant financial sustainability concerns given the company's $561.7M retained earnings deficit. Investors may face substantial volatility as the firm continues to rely on external financing or asset monetization to fund its ambitious R&D agenda amidst a competitive therapeutic landscape.
About AGIOS PHARMACEUTICALS, INC.
Agios Pharmaceuticals is a leading precision medicine company developing next-generation small molecule therapies across oncology, rare disease, and immunology. Operating primarily in the United States and Europe, the firm leverages its unique proprietary platforms to create transformative treatments for patients with limited therapeutic options.
Analysis
Management Discussion
The company reported a substantial net loss of $412.8M in 2025, continuing a trend of high operational expenditures driven by research and development costs totaling $339.5M. Despite this negative cash flow from operations, the firm maintained a healthy cash position of $89.1M and successfully executed major investing activities with $377.2M in cash flow from investing, likely reflecting asset sales or strategic acquisitions. Revenue growth remains robust at $54.0M compared to $36.5M the prior year, indicating market traction despite profitability challenges.
Industry Overview
The pharmaceutical industry is currently shifting towards precision medicine approaches that target specific genetic mutations, creating opportunities for companies like Agios to develop high-value niche therapies. While regulatory pathways have become more rigorous for novel mechanisms, successful approvals in oncology can command premium pricing and secure long-term market exclusivity.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $14.2M | $26.8M | $36.5M | $54.0M |
| Cost of Revenue | $1.7M | $2.9M | $4.2M | $6.3M |
| Gross Profit | $12.5M | $23.9M | $32.3M | $47.7M |
| Operating Expenses | $401.6M | $415.4M | $458.1M | $519.8M |
| Operating Income | $-389.0M | $-391.5M | $-425.7M | $-472.1M |
| R&D | $279.9M | $295.5M | $301.3M | $339.5M |
| G&A | $121.7M | $119.9M | $156.8M | $180.3M |
| Stock-Based Comp | $49.3M | $44.8M | $42.8M | $52.6M |
| Depreciation | $8.4M | $6.6M | $5.7M | $5.2M |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $157.2M | $39.4M | $1.14B | $58.3M |
| Interest Income | $12.8M | — | — | — |
| Pre-Tax Income | $-231.8M | $-352.1M | $718.0M | $-413.8M |
| Income Tax | $0 | $0 | $44.2M | $-1.0M |
| Continuing Ops | $-231.8M | $-352.1M | $673.7M | $-412.8M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-231.8M | $-352.1M | $673.7M | $-412.8M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-231.8M | $-352.1M | $673.7M | $-412.8M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $832.8M | $833.8M | $965.6M | $942.1M |
| Cash & Equivalents | $139.3M | $88.2M | $76.2M | $89.1M |
| Inventory | $8.5M | $19.1M | $27.6M | $32.9M |
| Prepaid Expenses | $39.0M | $35.0M | $40.2M | $44.1M |
| Other Current Assets | $646.1M | $691.5M | $821.6M | $775.9M |
| Long-Term Assets | $405.9M | $103.3M | $697.6M | $355.2M |
| PP&E (Net) | $23.0M | $15.4M | $11.7M | $10.8M |
| Operating Leases | $65.1M | $54.4M | $42.9M | $30.5M |
| Other LT Assets | $317.8M | $33.5M | $643.0M | $313.9M |
| Total Assets | $1.24B | $937.1M | $1.66B | $1.30B |
| Current Liabilities | $62.6M | $68.0M | $81.2M | $82.2M |
| Accounts Payable | $18.6M | $9.8M | $16.6M | $18.4M |
| Current Leases | $13.7M | $15.0M | $16.8M | $18.4M |
| Other Current Liab | $0 | $0 | $871.0K | $0 |
| Long-Term Liabilities | $75.3M | $58.1M | $41.1M | $21.9M |
| LT Operating Leases | $72.0M | $57.0M | $40.2M | $21.8M |
| Other LT Liab | $3.3M | $1.2M | $880.0K | $90.0K |
| Total Liabilities | $137.9M | $126.1M | $122.2M | $104.1M |
| Shareholders' Equity | $1.10B | $811.0M | $1.54B | $1.19B |
| Retained Earnings | $-470.6M | $-822.6M | $-148.9M | $-561.7M |
| Treasury Stock | $802.5M | $802.5M | $802.5M | $802.5M |
| Total L&E | $1.24B | $937.1M | $1.66B | $1.30B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-231.8M | $-352.1M | $673.7M | $-412.8M |
| Non-Cash Adjustments | $-82.1M | $60.4M | $-1.08B | $43.0M |
| Working Capital Changes | $4.4M | $-4.3M | $11.5M | $-3.2M |
| Cash from Operations | $-309.5M | $-296.1M | $-389.8M | $-373.0M |
| Capital Expenditures | $4.9M | $999.0K | $1.7M | $4.3M |
| Cash from Investing | $243.3M | $239.6M | $363.4M | $377.2M |
| Cash from Financing | $2.4M | $5.4M | $14.4M | $8.7M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-63.9M | $-51.1M | $-12.0M | $12.9M |
| Beginning Cash | $203.1M | $139.3M | $88.2M | $76.2M |
| Ending Cash | $139.3M | $88.2M | $76.2M | $89.1M |
Frequently Asked Questions
How does AGIOS PHARMACEUTICALS, INC. make money?
Oncology therapies targeting specific genetic mutations such as MYD88, KRAS, and JAK; Rare disease programs including treatments for Fabry disease and other metabolic disorders; Immunology solutions focusing on inflammatory conditions and autoimmune diseases; Platform technology licensing and collaboration revenues.
What are the main risks for AGIO?
Significant cash burn rate driven by heavy R&D investments leading to potential dilution or need for additional financing; Regulatory hurdles including FDA approval uncertainties for novel mechanisms of action; Competition from larger pharmaceutical players entering the oncology and rare disease spaces; Potential failure of late-stage clinical trials which could materially impact the pipeline valuation.
What is AGIO's competitive advantage?
Proprietary small molecule discovery platforms enabling the creation of highly selective drugs with reduced off-target effects; Strong pipeline depth in oncology and rare diseases addressing unmet medical needs; Strategic partnerships and collaborations that provide significant cash infusions and commercial reach without large upfront capital expenditures.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.